Fagron Compounding Services, LLC d/b/a Fagron Sterile Services acquires US Compounding, Inc. (2021)

Deal facts

Buyer: Fagron Compounding Services, LLC d/b/a Fagron Sterile Services
Target: US Compounding, Inc.
Deal value: Not disclosed
Announced: 5 August 2021
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash, deferred

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

30 Jul 2021CompletedClosed
Fagron Compounding Services, LLC d/b/a Fagron Sterile Services completes acquisition of US Compounding, Inc.
Item 1.01 Entry into Material Definitive Agreement On July 30, 2021, Adamis Pharmaceuticals Corporation (the “Company”) and the Company’s wholly-owned subsidiary US Compounding, Inc. (“USC”) entered into an Asset Purchase Agreement (the “Agreement”) effective as of July 30, 2021 (the “Effective Date”) with Fagron Compounding Services, LLC d/b/a Fagron Sterile Services (the “Purchaser”), providing
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of US Compounding, Inc by Fagron Compounding Services, LLC d/b/a Fagron Sterile Services. Announced on 5 August 2021, this transaction represents a strategic consolidation within the US healthcare sector. The deal structure is specific: it is an asset sale rather than a full equity transfer. This distinction matters for the SME founder reading this. It means the buyer is acquiring specific operational capabilities and likely customer contracts while leaving behind legacy liabilities or unwanted debt. The consideration mix of cash and deferred payment suggests the buyer sought to manage immediate capital outlay while aligning future payouts with the performance of the acquired assets.

The use of deferred consideration in an asset sale introduces a layer of commercial risk that requires careful navigation. Unlike a clean cash exit, the seller remains exposed to the operational success of the transferred assets post-close. In the highly regulated healthcare environment, this often triggers change-of-control covenants or specific regulatory clearances. While the deal is marked as completed, the deferred element implies that the final value was contingent on future milestones or the smooth transition of sterile compounding services. For any founder in this space, understanding that the sale price is not fully fixed at signing is a critical lesson. The regulatory context for sterile compounding is strict, and any failure to maintain compliance during the transition period could jeopardise the deferred portion of the deal.

We believe this transaction highlights the value of niche expertise in a consolidating market. Fagron Sterile Services, as the buyer, clearly identified a gap in their US footprint that US Compounding, Inc filled. The asset sale mechanism allowed them to pick and choose the most valuable parts of the target business without inheriting the whole corporate entity. This is a common tactic when a target has complex history or when the buyer only needs specific facilities or licences. It allows for a cleaner integration but demands precise legal drafting to define exactly what is being transferred. The SME founder must ensure that the scope of the asset sale is unambiguous to avoid disputes over what constitutes the "business" being sold.

Your immediate action this week is to map your own business assets against potential regulatory hurdles. Identify which licences, contracts, or intellectual property rights are essential for your valuation and which are merely administrative burdens. If you are considering an asset sale, draft a term sheet that explicitly lists the deferred payment triggers and the specific compliance standards required to unlock those funds. Do not assume the buyer will absorb operational friction; define the handover criteria now.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2021 deals More asset sale deals More from Fagron Compounding Services, LLC d/b/a Fagron Sterile Services All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC to acquire Selectis Health, Inc.

GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC and Selectis Health, Inc. entered the Exit Mode archive.

Buyer: GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC
Target: Selectis Health, Inc.
Deal value: USD 15,700,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

15 April 2026CompletedHealthcare

MeiraGTx Holdings plc to acquire Janssen Pharmaceuticals, Inc.

MeiraGTx Holdings plc and Janssen Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: MeiraGTx Holdings plc
Target: Janssen Pharmaceuticals, Inc.
Deal value: USD 25,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

7 April 2026Firm intentionHealthcare

Supernus Pharmaceuticals, Inc. to acquire Navitor Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. and Navitor Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Supernus Pharmaceuticals, Inc.
Target: Navitor Pharmaceuticals, Inc.
Deal value: USD 350,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

30 March 2026Firm intentionHealthcare

SCYNEXIS, Inc. to acquire Poxel SA

SCYNEXIS, Inc. and Poxel SA entered the Exit Mode archive.

Buyer: SCYNEXIS, Inc.
Target: Poxel SA
Deal value: USD 8,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals France deals

25 March 2026CompletedHealthcare

Vireo Health of Rocky Mountain, LLC to acquire Medicine Man Technologies, Inc. d/b/a Schwazze

Vireo Health of Rocky Mountain, LLC and Medicine Man Technologies, Inc. d/b/a Schwazze entered the Exit Mode archive.

Buyer: Vireo Health of Rocky Mountain, LLC
Target: Medicine Man Technologies, Inc. d/b/a Schwazze
Deal value: USD 111,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

Buyer history